Medtronic obtains FDA approval to utilise Simplera Sync glucose sensor integrated with insulin pumps

Medtronic has received FDA approval to integrate its Simplera Sync glucose sensor with the MiniMed 780G insulin pump, advancing its automated insulin delivery (AID) system. The Simplera Sync is a smaller, fingerstick-free sensor that eliminates the need for adhesive tape, improving user comfort. This update allows Medtronic to better compete in the diabetes tech market, particularly after resolving an FDA warning letter in 2023. The 780G pump, approved shortly before the warning was lifted, features meal detection technology and supports glucose targets as low as 100 mg/dL. Medtronic plans a limited launch of the integrated system this fall and expects the Simplera Sync—alongside a new CGM being co-developed with Abbott—to help grow its U.S. diabetes business. The company also aims to expand the 780G system’s label for use in patients with Type 2 diabetes. This strategic move positions Medtronic more strongly against rivals like Tandem, Insulet, and Abbott.

28-04-2025